June 21, 2017
2 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: Results of LATITUDE trial reinforce long-hypothesized theory in prostate cancer treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — The results of the LATITUDE trial demonstrated that the addition of abiraterone acetate with prednisone to standard hormonal therapy led to a decreased risk for death in men with high-risk, metastatic prostate cancer.
In this video from the ASCO Annual Meeting, Donald L. “Skip” Trump, MD, FACP, executive director of Inova Schar Cancer Institute and a HemOnc Today Editorial Board member, discusses the results of the trial and its significance.
“[The trial] supports the long-hypothesized theory that total androgen deprivation can be more successful than castration alone,” Trump said.